# Efficacy and Safety Study of the Therapeutic Vaccine PEP223 in Prostate Cancer Patients

> **NCT00895466** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Pepscan Therapeutics** · enrollment: 12 (estimated)

## Conditions studied

- Prostate Cancer

## Interventions

- **BIOLOGICAL:** PEP-223/CoVaccine HT

## Key facts

- **NCT ID:** NCT00895466
- **Lead sponsor:** Pepscan Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2008-10
- **Primary completion:** 2009-12
- **Final completion:** —
- **Target enrollment:** 12 (ESTIMATED)
- **Last updated:** 2009-05-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00895466

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00895466, "Efficacy and Safety Study of the Therapeutic Vaccine PEP223 in Prostate Cancer Patients". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00895466. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*